Can on‑abotulinumtoxinA be used as an adjunctive treatment for adults with treatment‑resistant major depressive disorder, and what are the appropriate dosing, contraindications, and monitoring guidelines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

OnabotulinumtoxinA for Treatment-Resistant Major Depressive Disorder

OnabotulinumtoxinA is NOT currently recommended as an adjunctive treatment for treatment-resistant major depressive disorder based on current clinical practice guidelines, despite emerging research evidence suggesting potential benefit.

Current Guideline Position

The most recent and authoritative guidelines on MDD treatment do not include botulinum toxin as a recommended intervention:

  • The 2023 American College of Physicians systematic review 1 comprehensively evaluated treatments for MDD and second-step strategies for treatment-resistant cases. Botulinum toxin was not included among evaluated or recommended treatments.

  • The 2022 VA/DoD Clinical Practice Guideline 2 specifically addresses treatment-resistant depression and recommends ketamine/esketamine for patients who have failed multiple adequate pharmacologic trials, but makes no mention of botulinum toxin.

  • The 2022 Delphi consensus guideline for treatment-resistant depression 3 defines TRD criteria and treatment approaches without including botulinum toxin among established interventions.

  • The 2016 ACP guideline 4 recommends cognitive behavioral therapy or second-generation antidepressants as first-line treatments, with no mention of botulinum toxin for any phase of treatment.

Why This Matters

The absence of botulinum toxin from all major depression treatment guidelines is significant. These guidelines were published between 2016-2023 and underwent rigorous systematic review processes. If botulinum toxin had sufficient evidence for clinical recommendation, it would have been included.

The Research Evidence (Not Yet Guideline-Level)

While research studies show promise, they have not yet translated into clinical practice recommendations:

Meta-analyses suggest potential efficacy:

  • A 2021 meta-analysis 5 of double-blind RCTs found onabotulinumtoxinA (20-40 IU dose range) more effective than placebo, but noted significant heterogeneity and identified important moderators (more effective in women, less effective with polypharmacy).

  • A 2020 meta-analysis 6 of 5 RCTs (417 participants) showed large effect size (Hedges' g = -0.82) for reducing depressive symptoms, with generally mild adverse events.

Individual trials show mixed results:

  • A 2020 phase 2 RCT 7 in 255 adult females found onabotulinumtoxinA 30 U approached significance (p=0.053) at week 6 but reached significance at weeks 3 and 9. The 50 U dose did not separate from placebo.

  • A 2014 RCT 8 (n=30) showed 55% HDRS-21 response rate with BTA versus 0% with placebo (p<0.0001), with effects lasting 24 weeks despite cosmetic effects wearing off at 12-16 weeks.

Critical Limitations

Why this research hasn't changed practice:

  1. Small sample sizes: Most studies involve fewer than 300 participants total
  2. Significant heterogeneity: Results vary substantially across studies
  3. Unclear optimal dosing: 30 U showed better results than 50 U in one trial 7, contradicting dose-response expectations
  4. Gender-specific effects: Evidence primarily in women; effectiveness in men unclear
  5. Mechanism uncertainty: The "facial feedback hypothesis" remains theoretical
  6. No long-term safety data: Studies limited to 24 weeks maximum
  7. Publication bias concerns: Field is relatively new with potential selective reporting

FDA Status

OnabotulinumtoxinA is FDA-approved for:

  • Cosmetic indications (glabellar lines, lateral canthal lines, forehead lines, platysma bands) 9
  • Chronic migraine
  • Various spasticity conditions
  • Cervical dystonia
  • Blepharospasm

It is NOT FDA-approved for depression 9. The FDA label carries a black box warning about distant spread of toxin effects, including potentially life-threatening swallowing and breathing difficulties.

What to Do Instead for Treatment-Resistant Depression

Follow established guideline-based approaches 2:

For patients failing 2+ adequate antidepressant trials:

  1. Ketamine or esketamine - Now recommended by VA/DoD guidelines 2 with consistent evidence for short-term efficacy in TRD
  2. Switching to different mechanism antidepressant - Based on Neuroscience-based Nomenclature 3
  3. Augmentation with atypical antipsychotics - Aripiprazole, brexpiprazole, quetiapine 2
  4. rTMS (repetitive transcranial magnetic stimulation) - 10-Hz rTMS has established evidence 2

Common Pitfalls to Avoid

  • Do not offer botulinum toxin as standard treatment for depression - It remains investigational
  • Do not confuse cosmetic improvement with antidepressant effect - The mechanism is hypothesized to be neurochemical, not simply improved appearance
  • Do not use off-label without informed consent - Patients must understand this is not guideline-recommended or FDA-approved for depression
  • Do not delay evidence-based treatments - Pursuing experimental options may postpone effective interventions

If Considering Off-Label Use (Research Context Only)

Should a clinician consider this in exceptional circumstances with full informed consent:

Dosing from research 7, 8:

  • 29-30 Units for females (glabellar region)
  • 39-40 Units for males (glabellar region)
  • Single treatment session
  • Effects may take 3-9 weeks to manifest
  • Duration of benefit: 12-24 weeks in studies

Contraindications (from FDA label) 9:

  • Infection at injection site
  • Known hypersensitivity to botulinum toxin
  • Neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome)
  • Pregnancy/breastfeeding considerations

Monitoring:

  • Depression scales (MADRS, HAM-D, BDI) at weeks 3,6,9,12
  • Adverse events: headache, eyelid ptosis, upper respiratory infection (most common in trials)
  • Watch for distant spread of toxin effects (black box warning)

However, this should only occur in research settings or after exhausting all guideline-recommended options.

Bottom Line

Stick with guideline-recommended treatments for treatment-resistant depression 1, 4, 2. The research on botulinum toxin is intriguing but insufficient to change clinical practice. For patients failing multiple adequate trials, prioritize ketamine/esketamine, medication switching/augmentation strategies, and neuromodulation techniques that have established evidence and guideline support.

References

Related Questions

Can onabotulinumtoxinA (Botox) be used to treat depression in adults with moderate-to-severe disease who have not responded to standard therapies?
I have major depressive disorder and anxiety, and I'm taking venlafaxine (Effexor) 75 mg daily and buspirone (Buspar) 10 mg twice daily, but I'm experiencing headache and excessive sleepiness; how should I manage these side effects?
For a 77-year-old male with anxiety and depression who is taking lamotrigine (Lamictal) 200 mg daily, mirtazapine (Remeron) 15 mg at bedtime, and duloxetine 30 mg in the morning and 60 mg at bedtime, should a low‑dose atypical antipsychotic be added to augment his regimen, and what dose and monitoring are recommended?
Is the current medication regimen appropriate for a patient with major depressive disorder, recurrent, moderate (F33.1), unspecified anxiety disorder (F41.9), and unspecified agoraphobia (F40.00) who is taking sertraline 150 mg orally daily, bupropion extended‑release 300 mg orally daily, aripiprazole 2 mg orally daily, buspirone 10 mg twice daily, mirtazapine 7.5 mg orally as needed for sleep, and propranolol 10 mg orally as needed for situational social anxiety, given that mood has plateaued with low‑grade depressive symptoms, increased irritability, impatience, and episodes of disproportionate anger?
How should I manage a patient with major depressive disorder and anxiety who is taking venlafaxine 225 mg daily and aripiprazole (Abilify) 10 mg daily but continues to have moderate depression and anxiety with blood‑pressure spikes during panic attacks?
What is the medical term for elevated uric acid levels accompanied by joint pain?
Can you create a 25‑slide PowerPoint presentation on recent updates in chronic obstructive pulmonary disease (COPD)?
What anesthetic precautions are recommended for a heart transplant recipient undergoing a cerebral angiogram?
When can preventive therapy be safely discontinued in patients with tension‑type headache or chronic migraine?
When should rivaroxaban be discontinued before surgery?
What is the appropriate dose of upadacitinib (Rinvoq) for a child weighing 12.5 kg?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.